News

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead
Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.
Why Novo Nordisk Stock Imploded This Week
Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...
Novo Nordisk Shares Plummet as Competition Weighs on Sales
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Novo Nordisk Cut Its Outlook and Named a New CEO. Its Stock Is Plummeting
U.S.-listed shares of Novo Nordisk (NVO) sank roughly 20% in premarket trading after the Danish drugmaker cut its full-year ...
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Novo Nordisk (NVO) Stock Outlook Positive with Focus on Diabetes and Obesity Drugs
Novo Nordisk A/S (NYSE:NVO) is a prominent global healthcare company that focuses on treating rare diseases, diabetes, and ...
A Medicare experiment could change who gets Ozempic
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Medicare and Medicaid move toward covering Ozempic and other weight loss drugs
Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...